z-logo
open-access-imgOpen Access
Macular oedema as manifestation of diabetic retinopathy
Author(s) -
М.М. Бикбов,
Бикбов Мухаррам Мухтарамович,
R. R. Fayzrakhmanov,
Файзрахманов Ринат Рустамович,
R.M. Zaynullin,
Зайнуллин Ринат Мухаметович,
Artur F. Zaynetdinov,
Зайнетдинов Артур Фанилевич,
Timur R. Gilmanshin,
Гильманшин Тимур Риксович,
M.R. Kalanov,
Каланов Марат Римович
Publication year - 2017
Publication title -
saharnyj diabet
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.155
H-Index - 12
eISSN - 2072-0378
pISSN - 2072-0351
DOI - 10.14341/dm8328
Subject(s) - medicine , diabetes mellitus , diabetic retinopathy , maculopathy , disease , retinopathy , ophthalmology , pathological , optometry , endocrinology
Diabetes mellitus is the third most dangerous disease of our time preceded by cardiovascular diseases and oncologic pathology. According to the International Diabetes Federation (January 1, 2016), worldwide approximately 415 million people aged 2079 years suffer from diabetes. The most significant manifestations of diabetes mellitus are lesions of the retina and blood vessels, which manifest as diabetic retinopathy and macular oedema, which lead to the inevitable loss of vision and disability in patients of working age. The existence of multile diagnostic methods and a broad classification provide an evidence of the complex nature of the pathological process of the macular zone in diabetes mellitus. However, to date, a single, generalised and accepted classification does not exist. Difficulties in the treatment of diabetic maculopathy are attributed to various forms of retinal lesions and ambiguities in the approach used to choose the disease management. It determines the importance of the development of diagnostic methods for the further correction of the standard treatment approach. New directions of surgical treatment allow relying on the best results of diabetic maculopathy treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here